View in EDS HTML Full Text PDF Full Text

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.

Saved in:
Bibliographic Details
Title: HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.
Authors: Cao W; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Xie S; Division of Hepatology, Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China., Hao H; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Deng W; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Zhang L; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Lu Y; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Liu R; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Wang S; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Li X; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Zhang Z; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Wei X; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Gao Z; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Yao L; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Wang S; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Gao Y; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Wang Y; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Xu M; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Hu L; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China., Xie Y; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.; Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China., Li M; Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.; HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.; Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.
Source: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2026 May 21; Vol. 16, pp. 1778016. Date of Electronic Publication: 2026 May 21 (Print Publication: 2026).
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2235-2988
DOI:10.3389/fcimb.2026.1778016